ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Educational Symposium

Uremic Toxin Removal with Dialysis: Effects of Middle Molecule Clearance on Clinical Outcomes

November 05, 2021 | 12:45 PM - 01:45 PM

Location: Simulive, Virtual Only

Session Description

Chronic hemodialysis is the most common form of kidney replacement therapy worldwide. Patients receiving hemodialysis long-term have a high burden of cardiovascular morbidity and mortality, which is not fully explained by traditional cardiovascular risk factors. Retention of uremic toxins is in part responsible for the high rate of chronic inflammation among patients receiving dialysis. Traditional hemodialysis technology removes primarily small molecules and has poor clearance capacity for large middle molecular uremic toxins. The latter has been associated with the development of inflammation and worsened cardiovascular morbidity and mortality. Newer hemodialysis technologies allow the removal of large middle molecular toxins.

This symposium discusses the role of middle molecules in the morbidity and mortality of patients with kidney failure and provides a review of novel dialysis technologies used to enhance middle molecular clearance and their potential benefits.

Support is provided by an educational grant from Baxter Healthcare Corporation.

Learning Objective(s)

  • Describe the principles of dialytic clearance of small and middle molecules
  • Examine the effects of middle molecular uremic toxins on inflammation and adverse clinical outcomes
  • Discuss the effects of novel dialytic techniques on middle molecule removal

Learning Pathway(s)

  • Dialysis


  • Anders H. Berg, MD, PhD